Mechanism of Action

ENHERTU is a specifically engineered HER2-directed antibody-drug
conjugate (ADC)1,2

HER2-directed mAb1

  • Provides targeted delivery of
    cytotoxic agent1,2
  • Consists of the same amino
    acid sequence as

Topoisomerase I inhibitor payload1,2,a

  • Highly potent payload is an exatecan derivative, known as DXd, with a short systemic half-life1,3
  • Upon release, membrane-permeable payload causes DNA damage and cell death, resulting in destruction of targeted tumor cells and surrounding cells, known as the bystander antitumor effect1,3,4

Tumor-selective cleavable linker1-3,a

  • Attaches payload to the antibody1
  • Linker-payload is stable in plasma2,3
  • Linker selectively cleaved by enzymes
    are upregulated in tumor cells1,3

ENHERTU has a homogeneous and high drug-to-antibody ratio of
~8 molecules of cytotoxic agent per antibody1-3,a,b

aBased on in vitro and in vivo non-clinical studies. The clinical relevance of these features is under investigation.

bADCs are a mixture of molecules in which the DAR is variable. Homogeneity of DAR refers to a mixture where there is low variability of DAR; the payload number per antibody falls into a narrow range.3

Ready to learn more about ENHERTU?
DAR, drug-to-antibody ratio; DNA, deoxyribonucleic acid; HER2, human epidermal growth factor receptor 2; mAb, monoclonal antibody.